Semaglutide vs Tirzepatide: research compound comparison
Both are studied in metabolic-pathway research. Semaglutide is a single GLP-1 receptor agonist; Tirzepatide is a dual GIP/GLP-1 receptor agonist. The dual mechanism is the primary structural difference investigated in preclinical metabolic models.
Semaglutide and Tirzepatide are among the most-discussed metabolic research peptides. They share the GLP-1 incretin pathway but differ in their receptor coverage.
Semaglutide
- A long-acting GLP-1 receptor agonist.
- Studied in preclinical models of glucose handling, insulin sensitivity, and weight regulation.
Tirzepatide
- A dual agonist at the GIP and GLP-1 receptors — the "twincretin" mechanism.
- Studied for the additive effects of co-activating both incretin pathways in metabolic models.
Retatrutide, a newer research compound, extends this further as a triple agonist (GIP / GLP-1 / glucagon).
All three are supplied by ADAM Molecular Research strictly for in-vitro and preclinical laboratory investigation. They are not FDA-approved drugs in our supply chain and are not for human or veterinary use. See the Metabolic pathway for the full set.
// Related research pathways